Announcements Trials
Browse Landscape

Phase

Phase 2 54Phase NA 30Phase 1/2 30Phase 1 30Phase EARLY_PHASE1 7Phase 3 5Phase 4 3Phase 2/3 3

Status

Completed 191Terminated 33Active not recruiting 30Unknown 28Recruiting 28Not yet recruiting 6Withdrawn 5Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 34Genitourinary 29Breast 25Thoracic 23Lymphoid 22Other hematologic neoplasm 15Gynecologic 14Head & Neck 10CNS 8Sarcoma 5Dermatologic 5Tumor-Agnostic 4Plasma cell 4Myeloid 3Endocrine 3Classical hematology 3Other solid neoplasm 1Other neoplasm 1Other 1NET 1

Conditions

Melanoma 3Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Keratosis, Actinic 1

Interventions

sargramostim 1cobimetinib 1Vorinostat 1Vemurafenib 1Solutions 1Sentinel Lymph Node Biopsy 1Saline Solution, Hypertonic 1Interferon-alpha 1Granulocyte-Macrophage Colony-Stimulating Factor 1Bortezomib 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Dermatologic × Clear all
NCT01826864 2020-07-27

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Jonsson Comprehensive Cancer Center

Phase 3 Withdrawn
Dermatologic

Melanoma

NCT03024060 2017-11-07

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

DUSA Pharmaceuticals, Inc.

Phase 3 Withdrawn
Dermatologic

Keratosis, Actinic

NCT02427893 2016-11-15

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 3 Withdrawn
Dermatologic

Melanoma

NCT01386398 2015-01-21

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00447356 2013-05-13

High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma

Hackensack Meridian Health

Phase 3 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡